Suicide gene therapy for the treatment of high-grade glioma
Standard
Suicide gene therapy for the treatment of high-grade glioma : past lessons, present trends, and future prospects. / Hossain, Jubayer A; Marchini, Antonio; Fehse, Boris; Bjerkvig, Rolf; Miletic, Hrvoje.
In: NEURO-ONCOL ADV, Vol. 2, No. 1, 10.07.2020, p. vdaa013.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Suicide gene therapy for the treatment of high-grade glioma
T2 - past lessons, present trends, and future prospects
AU - Hossain, Jubayer A
AU - Marchini, Antonio
AU - Fehse, Boris
AU - Bjerkvig, Rolf
AU - Miletic, Hrvoje
N1 - © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2020/7/10
Y1 - 2020/7/10
N2 - Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.
AB - Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.
U2 - 10.1093/noajnl/vdaa013
DO - 10.1093/noajnl/vdaa013
M3 - SCORING: Review article
C2 - 32642680
VL - 2
SP - vdaa013
JO - NEURO-ONCOL ADV
JF - NEURO-ONCOL ADV
SN - 2632-2498
IS - 1
ER -